XTX Topco Ltd Raises Position in Progyny, Inc. $PGNY

XTX Topco Ltd increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 430.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,142 shares of the company’s stock after buying an additional 46,367 shares during the quarter. XTX Topco Ltd owned about 0.07% of Progyny worth $1,257,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PGNY. Cetera Trust Company N.A increased its stake in Progyny by 303.1% during the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock worth $29,000 after buying an additional 985 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Progyny during the first quarter valued at about $44,000. Militia Capital Partners LP increased its position in shares of Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock worth $45,000 after acquiring an additional 1,000 shares during the last quarter. Brooklyn Investment Group lifted its stake in shares of Progyny by 5,216.4% in the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company’s stock worth $72,000 after acquiring an additional 3,182 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in shares of Progyny by 57.9% in the first quarter. AlphaQuest LLC now owns 5,668 shares of the company’s stock worth $127,000 after acquiring an additional 2,079 shares in the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Price Performance

PGNY stock opened at $26.39 on Friday. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of 41.88, a price-to-earnings-growth ratio of 2.08 and a beta of 1.29. The company has a 50-day moving average of $21.75 and a two-hundred day moving average of $22.14. Progyny, Inc. has a 52-week low of $13.86 and a 52-week high of $27.51.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.39 by $0.06. The firm had revenue of $313.35 million during the quarter, compared to analysts’ expectations of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.Progyny’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same period last year, the business earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. Equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insider Activity at Progyny

In other news, CFO Mark S. Livingston sold 21,303 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $25.50, for a total value of $543,226.50. Following the completion of the transaction, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This represents a 30.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Peter Anevski bought 79,500 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The shares were bought at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the transaction, the chief executive officer directly owned 680,251 shares in the company, valued at $16,523,296.79. This trade represents a 13.23% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 9.40% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on PGNY shares. Raymond James Financial set a $28.00 target price on Progyny in a report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research report on Wednesday, October 8th. Canaccord Genuity Group upped their price objective on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. KeyCorp upgraded shares of Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price target on the stock in a research note on Tuesday, November 11th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Progyny has an average rating of “Moderate Buy” and a consensus target price of $27.33.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.